<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02330484</url>
  </required_header>
  <id_info>
    <org_study_id>CCEMD-026</org_study_id>
    <nct_id>NCT02330484</nct_id>
  </id_info>
  <brief_title>Affect of Incentive Strategy on the Adherence to Medication Among Patients With Type 2 Diabetes</brief_title>
  <official_title>Affect of Incentive Strategy on the Adherence to Medication Among Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on patients' HbA1c improvement, this study aims to establish an incentive strategy to&#xD;
      family physicians and patients respectively to evaluate the affect on the adherence to&#xD;
      medication among patients with type2 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      First step: In this study, the investigators will conduct an open-label controlled randomized&#xD;
      cluster trial to enroll 400 eligible and voluntary patients with type 2 diabetes from the&#xD;
      community. 16 physicians will be involved in this study for patient management. Each&#xD;
      physician will care at least 20 patients as a random unit which will be divided into 4 groups&#xD;
      for baseline assessment including demographic characteristics, diabetes diagnosis and&#xD;
      treatment, complication, biochemical indexes and self-management. The involved patients and&#xD;
      physicians will receive related training. The patients will sign the informed consent form.&#xD;
&#xD;
      Second step: This study aims to give incentives to physicians or patients or both the&#xD;
      physicians and patients based on HbA1c improvement. All the patients will sign the informed&#xD;
      consent form. Regarding to the control group, health courses and community management will be&#xD;
      given as usual. the investigators will evaluate the condition of patients' medication&#xD;
      adherence after giving the incentives.&#xD;
&#xD;
      Third step: MEMS will be used in the intervention to monitoring patients' medication&#xD;
      adherence. As a monitoring instrument, MEMS (Aardex, Zurich, Switzerland) is a plastic&#xD;
      container with a spring-loaded device in the cap. Each time the bottles is opened for at&#xD;
      least 3 seconds, the time and date of opening are recorded and saved. Based on the research&#xD;
      data and the HbA1c improvement, this study will analyze the other factors which affect the&#xD;
      patients' adherence to medication. Meanwhile, the investigators will collect patients'&#xD;
      information such as blood pressure, biochemical index, complications related to diabetes,&#xD;
      life quality, self-management, life style, health behavior, medications, health expenditure&#xD;
      so as to evaluate the affect of incentive strategy on the adherence to medication among&#xD;
      patients with type 2 diabetes.&#xD;
&#xD;
      Endpoint of the study:&#xD;
&#xD;
      The study will be ended in 12 months, endpoint measurement indicators are listed below:&#xD;
&#xD;
        1. The study will be ended in 12 months&#xD;
&#xD;
        2. Patient's drop out of the study&#xD;
&#xD;
        3. Stopping taking oral hypoglycemic drugs&#xD;
&#xD;
        4. The diabetic condition worsen, needs surgery or hospitalization treatment&#xD;
&#xD;
        5. Frequency of severe hypoglycemia or other complications that can not continue the study&#xD;
&#xD;
        6. Death of the patient&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hypoglycemic Medication adherence rates using electronically monitored adherence (MEMS cap) data</measure>
    <time_frame>12 months</time_frame>
    <description>MEMS will be used in the intervention to monitoring patients' medication adherence. As a monitoring instrument, MEMS (Aardex, Zurich, Switzerland) is a plastic container with a spring-loaded device in the cap. Each time the bottles is opened for at least 3 seconds, the time and date of opening are recorded and saved.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Self-report medication adherence</measure>
    <time_frame>12 months</time_frame>
    <description>The investigators assess adherence with MMAS 8-item version and BMQ-specific.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of HbA1c</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score on the Diabetes Quality Of Life</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MEMS cap data compared to PHQ-9 and AIS assessment</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>incentives to physicians</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Give incentives to physicians according to patients' HbA1c improvement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>incentives to patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Give incentives to patients according to their HbA1c improvement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>incentives to both physicians and patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intervention mode: Give incentives to physicians and patients according to patients' HbA1c improvement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group with no incentives</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Give incentives to patients based on their own HbA1c improvement</intervention_name>
    <description>Give incentives to patients based on their own HbA1c improvement</description>
    <arm_group_label>incentives to both physicians and patients</arm_group_label>
    <arm_group_label>incentives to patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Give incentives to physician based on their patient's HbA1c improvement</intervention_name>
    <description>Give incentives to physician based on their patient's HbA1c improvement</description>
    <arm_group_label>incentives to both physicians and patients</arm_group_label>
    <arm_group_label>incentives to physicians</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed type 2 diabetes patients (ICD9) according to the medical record and&#xD;
             patient's disease history&#xD;
&#xD;
          2. 40 to 74 years old&#xD;
&#xD;
          3. Diagnosis type 2 diabetes more than 6 months&#xD;
&#xD;
          4. Take at least one kind of oral hypoglycemic medication(including insulin injection)&#xD;
&#xD;
          5. Got treatment in community hospitals or follow up for more than 12 months&#xD;
&#xD;
          6. Have medical insurance&#xD;
&#xD;
          7. Stable condition with no adverse indication&#xD;
&#xD;
          8. Participate in this study voluntarily and sign the inform consent from&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Terminal illness&#xD;
&#xD;
          2. Serious hearing and visual disorder&#xD;
&#xD;
          3. Intend to receive selective surgery, to get pregnancy and breast feeding in three&#xD;
             months&#xD;
&#xD;
          4. Demnentia or communication disorders&#xD;
&#xD;
          5. Mental disorders&#xD;
&#xD;
          6. The paralyzed or the handicapped&#xD;
&#xD;
          7. Expected survival time less than one-year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liebin Zhao, MSM</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai Clinical Centre for Endocrinology and Metabolism</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ruijin hospital, Shanghai Jiao-Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>December 24, 2014</study_first_submitted>
  <study_first_submitted_qc>December 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2015</study_first_posted>
  <last_update_submitted>December 31, 2014</last_update_submitted>
  <last_update_submitted_qc>December 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Guang Ning</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Community managementï¼Œ incentives, Medication Adherence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

